切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2017, Vol. 06 ›› Issue (06) : 494 -498. doi: 10.3877/cma.j.issn.2095-3232.2017.06.017

所属专题: 文献

临床研究

合并肝硬化的小肝内胆管细胞癌MRI强化特征分析和鉴别诊断
伍路1, 黄彬1, 霍雷1, 夏勇1, 闫振林1, 沈锋1,()   
  1. 1. 200438 上海,第二军医大学附属东方肝胆外科医院肝脏外科
  • 收稿日期:2017-08-23 出版日期:2017-12-10
  • 通信作者: 沈锋
  • 基金资助:
    国家自然基金委创新群体项目(81521091); 国家自然科学基金(81301302); 上海市科委西医引导项目(15411988100)

MRI enhancement features and differential diagnosis of small intrahepatic cholangiocarcinoma with liver cirrhosis

Lu Wu1, Bin Huang1, Lei Huo1, Yong Xia1, Zhenlin Yan1, Feng Shen1,()   

  1. 1. Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital Affiliated to the Second Military Medical University, Shanghai 200438, China
  • Received:2017-08-23 Published:2017-12-10
  • Corresponding author: Feng Shen
  • About author:
    Corresponding author: Shen Feng, Email:
引用本文:

伍路, 黄彬, 霍雷, 夏勇, 闫振林, 沈锋. 合并肝硬化的小肝内胆管细胞癌MRI强化特征分析和鉴别诊断[J/OL]. 中华肝脏外科手术学电子杂志, 2017, 06(06): 494-498.

Lu Wu, Bin Huang, Lei Huo, Yong Xia, Zhenlin Yan, Feng Shen. MRI enhancement features and differential diagnosis of small intrahepatic cholangiocarcinoma with liver cirrhosis[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2017, 06(06): 494-498.

目的

探讨合并肝硬化的小肝内胆管细胞癌(ICC)的MRI强化特征和鉴别诊断。

方法

本前瞻性队列研究对象为2012年12月至2015年12月在第二军医大学附属东方肝胆外科医院接受外科手术治疗的56例合并肝硬化的小ICC患者。其中男40例,女16例;年龄29~74岁,中位年龄54岁。患者均签署知情同意书,符合医学伦理学规定。患者行肝脏动态增强MRI检查,静脉注射钆喷酸葡胺造影剂。增强MRI扫描包括肝动脉期、门静脉期和延迟期。采用kappa系数评估观察者间判读强化类型的一致性。强化类型与病灶直径相关性分析采用Fisher确切概率法。

结果

观察者对病灶强化类型的判读一致性评价为优异(κ=0.82)。52% (29/56)小ICC表现为渐进型强化,36% (20/56)为稳定型强化,5%(3/56)为快进快出型强化,7%(4/56)为快进+衰退型强化。直径<20 mm病灶最常见的强化类型为稳定型强化,20~30 mm病灶最常见为渐进型强化,小ICC的强化类型与病灶直径具有相关性(P=0.006)。

结论

合并肝硬化的小ICC强化类型主要为稳定型和渐进型,但少部分表现为快进快出的强化特征,此类型与小肝癌强化类似,为两者鉴别诊断的重点和难点。

Objective

To investigate the MRI enhancement features and differential diagnosis of small intrahepatic cholangiocarcinoma (ICC) combined with liver cirrhosis.

Methods

A total of 56 patients with small ICC combined with liver cirrhosis who underwent surgical treatment in the Eastern Hepatobiliary Surgery Hospital Affiliated to the Second Military Medical University between December 2012 and December 2015 were enrolled in this prospective cohort study. Among them, 40 cases were male and 16 were female, age 29-74 years old with a median age of 54 years old. The informed consents of all patients were obtained and the local ethical committee approval was received. All the patient underwent hepatic dynamic enhanced MRI examination and intravenous injection of Gd-DTPA contrast. The enhanced MRI imaging included hepatic arterial phase, portal vein phase and delayed phase. Inter-observer consistency of determining enhancement types was assessed by kappa coefficient. Correlation between enhancement type and lesion diameter was analyzed by Fisher's exact probability test.

Results

The inter-observer consistency of determing lesion enhancement types was excellent (κ=0.82). 52%(29/56) of the patients with small ICC presented as progressive enhancement pattern, 36%(20/56) as stable pattern, 5%(3/56) as fast-in and fast-out pattern and 7%(4/56) as fast-in + recession pattern. The most common enhancement pattern for the lesions with a diameter of less than 20 mm was stable pattern, and progressive pattern for the lesions with a diameter of 20-30 mm. The enhancement pattern of small ICC was correlated with the diameter of lesion (P=0.006).

Conclusions

Most common MRI enhancement pattern for the patients with small ICC combined with liver cirrhosis are stable and progressive pattern. But some presents as fast-in and fast-out pattern, and this pattern is similar to that of small hepatocellular carcinoma, which is the key and difficult point for differential diagnosis between them.

表1 肝脏增强MRI技术参数
表2 肝内胆管细胞癌直径与动态强化类型的关系(例)
[1]
Zhang H, Yang T, Wu M, et al. Intrahepatic cholangiocarcinoma: epidemiology, risk factors, diagnosis and surgical management[J]. Cancer Lett, 2016, 379(2):198-205.
[2]
Razumilava N, Gores GJ. Cholangiocarcinoma[J]. Lancet, 2014, 383(9935):2168-2179.
[3]
Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma[J]. J Hepatol, 2014, 60(6):1268-1289.
[4]
Patel T. Cholangiocarcinoma--controversies and challenges[J]. Nat Rev Gastroenterol Hepatol, 2011, 8(4):189-200.
[5]
Zhou H, Wang H, Zhou D, et al. Hepatitis B virus-associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma may hold common disease process for carcinogenesis[J]. Eur J Cancer, 2010, 46(6):1056-1061.
[6]
Peng NF, Li LQ, Qin X, et al. Evaluation of risk factors and clinicopathologic features for intrahepatic cholangiocarcinoma in Southern China: a possible role of hepatitis B virus[J]. Ann Surg Oncol, 2011, 18(5):1258-1266.
[7]
Jeong S, Tong Y, Sha M, et al. Hepatitis B virus-associated intrahepatic cholangiocarcinoma: a malignancy of distinctive characteristics between hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. Oncotarget, 2017, 8(10):17292-17300.
[8]
Li R, Cai P, Ma KS, et al. Dynamic enhancement patterns of intrahepatic cholangiocarcinoma in cirrhosis on contrast-enhanced computed tomography: risk of misdiagnosis as hepatocellular carcinoma[J]. Sci Rep, 2016(6):26772.
[9]
Fujita N, Asayama Y, Nishie A, et al. Mass-forming intrahepatic cholangiocarcinoma: enhancement patterns in the arterial phase of dynamic hepatic CT-correlation with clinicopathological findings[J]. Eur Radiol, 2017, 27(2):498-506.
[10]
Koh J, Chung YE, Nahm JH, et al. Intrahepatic mass-forming cholangiocarcinoma: prognostic value of preoperative gadoxetic acid-enhanced MRI[J]. Eur Radiol, 2016, 26(2):407-416.
[11]
Huang B, Wu L, Lu XY, et al. Small intrahepatic cholangiocarcinoma and hepatocellular carcinoma in cirrhotic livers may share similar enhancement patterns at multiphase dynamic MR imaging[J]. Radiology, 2016, 281(1): 150-157.
[12]
Hwang J, Kim YK, Min JH, et al. Capsule, septum, and T2 hyperintense foci for differentiation between large hepatocellular carcinoma (≥5 cm) and intrahepatic cholangiocarcinoma on gadoxetic acid MRI[J]. Eur Radiol, 2017, DOI: 10.1007/s00330-017-4846-4[Epub ahead of print].
[13]
Kang Y, Lee JM, Kim SH, et al. Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images[J]. Radiology, 2012, 264(3):751-760.
[14]
Kim SA, Lee JM, Lee KB, et al. Intrahepatic mass-forming cholangiocarcinomas: enhancement patterns at multiphasic CT, with special emphasis on arterial enhancement pattern--correlation with clinicopathologic findings[J]. Radiology, 2011, 260(1):148-157.
[15]
Iavarone M, Piscaglia F, Vavassori S, et al. Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis[J]. J Hepatol, 2013, 58(6):1188-1193.
[16]
Rimola J, Forner A, Tremosini S, et al. Non-invasive diagnosis of hepatocellular carcinoma ≤2 cm in cirrhosis. diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI[J]. J Hepatol, 2012, 56(6):1317-1323.
[17]
Zhang N, Gu J, Yin L, et al. Incorporation of alpha-fetoprotein (AFP) into subclassification of BCLC C stage hepatocellular carcinoma according to a 5-year survival analysis based on the SEER database[J]. Oncotarget, 2016, 7(49):81389-81401.
[18]
Yoh T, Seo S, Hatano E, et al. A novel biomarker-based preoperative prognostic grading system for predicting survival after surgery for intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2017, 24(5): 1351-1357.
[19]
Rimola J, Forner A, Reig M, et al. Cholangiocarcinoma in cirrhosis: absence of contrast was hout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma[J]. Hepatology, 2009, 50(3):791-798.
[20]
Sheng RF, Zeng MS, Rao SX, et al. MRI of small intrahepatic mass-forming cholangiocarcinoma and atypical small hepatocellular carcinoma (≤3 cm) with cirrhosis and chronic viral hepatitis: a comparative study[J]. Clin Imaging, 2014, 38(3):265-272.
[1] 项文静, 徐燕, 茹彤, 郑明明, 顾燕, 戴晨燕, 朱湘玉, 严陈晨. 神经学超声检查在产前诊断胼胝体异常中的应用价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(05): 470-476.
[2] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[3] 庄若语, 杭明辉, 李文华, 张霆, 侯炜. 膝骨关节炎半定量磁共振评分研究进展[J/OL]. 中华关节外科杂志(电子版), 2024, 18(04): 545-552.
[4] 谢丽春, 欧庆芬, 张秋萍, 叶升. 简化和标准肝脏MRI方案在结直肠癌肝转移患者随访中的临床应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 434-437.
[5] 贺健, 张骊, 王洪海, 蒋文涛. 肝移植术后脾功能亢进转归及治疗研究进展[J/OL]. 中华移植杂志(电子版), 2024, 18(05): 310-314.
[6] 王浩源, 汪海洋, 孙建明, 陈以宽, 祁小桐, 唐博. 腹腔镜与开放修补对肝硬化腹外疝患者肝功能及凝血的影响[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 654-659.
[7] 刘明辉, 葛方明. MRI 对腹股沟疝修补术后患者早期并发症的评估价值研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 579-583.
[8] 蔡艺丹, 方坚, 张志强, 陈莉, 张世安, 夏磊, 阮梅, 李东良. 经颈静脉肝内门体分流术对肝硬化门脉高压患者肠道菌群及肝功能的影响[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(05): 285-293.
[9] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[10] 邓万玉, 陈富, 许磊波. 肝硬化与非肝硬化乙肝相关性肝癌患者术后无复发生存比较及其影响因素分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 670-674.
[11] 臧书芹, 陈巧玲, 江思源, 朱晓明, 沈浮, 王颢, 张卫, 邵成伟. 基于直肠高分辨MRI的直肠侧系膜分析及其临床价值的研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(04): 312-320.
[12] 张立俊, 孙存杰, 胡春峰, 孟冲, 张辉. MSCT、DCE-MRI 评估术前胃癌TNM 分期的准确性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 519-523.
[13] 崔健, 夏青, 林云, 李光玲, 李心娜, 王位. 血小板与淋巴细胞比值、免疫球蛋白、心肌酶谱及心电图对中老年肝硬化患者病情及预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 400-406.
[14] 秦相清, 朱陈, 张海银. 构建诺模图模型预测肝硬化食管胃底静脉曲张出血的风险[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(04): 330-335.
[15] 金安松, 邹玉松, 刘玖涛, 薛凤麟, 庞爱兰. 孤立性颅内浆细胞瘤一例及相关文献复习[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(05): 495-500.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?